Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs—part a: renal, penile, and testicular tumours. European Urol. 2016;70:93–105. https://doi.org/10.1016/j.eururo.2016.02.029.

Article  Google Scholar 

Dabestani S, Thorstenson A, Lindblad P, Harmenberg U, Ljungberg B, Lundstam S. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol. 2016;34:1081–6. https://doi.org/10.1007/s00345-016-1773-y.

Article  PubMed  Google Scholar 

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:706–20. https://doi.org/10.1093/annonc/mdz056.

Article  CAS  PubMed  Google Scholar 

Roussel E, Capitanio U, Kutikov A, Oosterwijk E, Pedrosa I, Rowe SP, et al. Novel imaging methods for renal mass characterization: a collaborative review. European Urol. 2022;81:476–88. https://doi.org/10.1016/j.eururo.2022.01.040.

Article  Google Scholar 

James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev. 2012;92:897–965. https://doi.org/10.1152/physrev.00049.2010.

Article  CAS  PubMed  Google Scholar 

Wei W, Rosenkrans ZT, Liu J, Huang G, Luo Q-Y, Cai W. ImmunoPET: concept, design, and applications. Chem Rev. 2020;120:3787–851. https://doi.org/10.1021/acs.chemrev.9b00738.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verhoeff SR, Oosting SF, Elias SG, van Es SC, Gerritse SL, Angus L, et al. [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to predict watchful waiting duration in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res. 2023;29:592–601. https://doi.org/10.1158/1078-0432.Ccr-22-0921.

Article  CAS  PubMed  Google Scholar 

Hekman MCH, Rijpkema M, Aarntzen EH, Mulder SF, Langenhuijsen JF, Oosterwijk E, et al. Positron emission tomography/computed tomography with (89)Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion. Eur Urol. 2018;74:257–60. https://doi.org/10.1016/j.eururo.2018.04.026.

Article  PubMed  Google Scholar 

Wei W, Younis MH, Lan X, Liu J, Cai W. Single-domain antibody theranostics on the horizon. J Nucl Med. 2022;63:1475–9. https://doi.org/10.2967/jnumed.122.263907.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krasniqi A, D’Huyvetter M, Devoogdt N, Frejd FY, Sorensen J, Orlova A, et al. Same-day imaging using small proteins: clinical experience and translational prospects in oncology. J Nucl Med. 2018;59:885–91. https://doi.org/10.2967/jnumed.117.199901.

Article  CAS  PubMed  Google Scholar 

Morris O, Fairclough M, Grigg J, Prenant C, McMahon A. A review of approaches to 18F radiolabelling affinity peptides and proteins. J Label Compd Radiopharm. 2018;62:4–23. https://doi.org/10.1002/jlcr.3634.

Article  CAS  Google Scholar 

Cleeren F, Lecina J, Bridoux J, Devoogdt N, Tshibangu T, Xavier C, et al. Direct fluorine-18 labeling of heat-sensitive biomolecules for positron emission tomography imaging using the Al18F-RESCA method. Nat Protoc. 2018;13:2330–47. https://doi.org/10.1038/s41596-018-0040-7.

Article  CAS  PubMed  Google Scholar 

Qin X, Guo X, Liu T, Li L, Zhou N, Ma X, et al. High in-vivo stability in preclinical and first-in-human experiments with [18F]AlF-RESCA-MIRC213: a 18F-labeled nanobody as PET radiotracer for diagnosis of HER2-positive cancers. European J Nucl Med Mol Imaging. 2022;50:302–13. https://doi.org/10.1007/s00259-022-05967-7.

Article  CAS  Google Scholar 

Flieswasser T, Van den Eynde A, Van Audenaerde J, De Waele J, Lardon F, Riether C, et al. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res. 2022;41:12. https://doi.org/10.1186/s13046-021-02215-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benhamouda N, Sam I, Epaillard N, Gey A, Phan L, Pham HP, et al. Plasma CD27, a surrogate of the intratumoral CD27-CD70 interaction, correlates with immunotherapy resistance in renal cell carcinoma. Clin Cancer Res. 2022;28:4983–94. https://doi.org/10.1158/1078-0432.Ccr-22-0905.

Article  CAS  PubMed  Google Scholar 

Jacobs J, Deschoolmeester V, Zwaenepoel K, Rolfo C, Silence K, Rottey S, et al. CD70: An emerging target in cancer immunotherapy. Pharmacol Ther. 2015;155:1–10. https://doi.org/10.1016/j.pharmthera.2015.07.007.

Article  CAS  PubMed  Google Scholar 

Huang RR, Chen Z, Kroeger N, Pantuck A, Said J, Kluger HM, et al. CD70 is consistently expressed in primary and metastatic clear cell renal cell carcinoma. Clin Genitourin Cancer. 2023. https://doi.org/10.1016/j.clgc.2023.12.003.

Article  PubMed  Google Scholar 

Ruf M, Mittmann C, Nowicka AM, Hartmann A, Hermanns T, Poyet C, et al. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma. Clin Cancer Res. 2015;21:889–98. https://doi.org/10.1158/1078-0432.CCR-14-1425.

Article  CAS  PubMed  Google Scholar 

Jilaveanu LB, Sznol J, Aziz SA, Duchen D, Kluger HM, Camp RL. CD70 expression patterns in renal cell carcinoma. Human Pathol. 2012;43:1394–9. https://doi.org/10.1016/j.humpath.2011.10.014.

Article  CAS  Google Scholar 

Li S, Chen D, Guo H, Liu D, Yang C, Zhang R, et al. The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling. Front Oncol. 2023;13:1240061. https://doi.org/10.3389/fonc.2023.1240061.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Panowski SH, Srinivasan S, Tan N, Tacheva-Grigorova SK, Smith B, Mak YSL, et al. Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma. Cancer Res. 2022;82:2610–24. https://doi.org/10.1158/0008-5472.CAN-21-2931.

Article  CAS  PubMed  Google Scholar 

Dewulf J, Flieswasser T, Delahaye T, Vangestel C, Miranda A, de Haard H, et al. Site-specific (68)Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models. EJNMMI Radiopharm Chem. 2023;8:8. https://doi.org/10.1186/s41181-023-00194-3.

Article  PubMed  PubMed Central  Google Scholar 

Ziaei V, Ghassempour A, Davami F, Azarian B, Behdani M, Dabiri H, et al. Production and characterization of a camelid single domain anti-CD22 antibody conjugated to DM1. Mol Cell Biochem. 2023. https://doi.org/10.1007/s11010-023-04741-z.

Article  PubMed  Google Scholar 

Zhang X, Liu C, Xie Y, Hu Q, Chen Y, Li J. Identification and characterization of blocking nanobodies against human CD70. Acta Biochim Biophys Sin (Shanghai). 2022;54:1518–27. https://doi.org/10.3724/abbs.2022141.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cleeren F, Lecina J, Bridoux J, Devoogdt N, Tshibangu T, Xavier C, et al. Direct fluorine-18 labeling of heat-sensitive biomolecules for positron emission tomography imaging using the Al(18)F-RESCA method. Nat Protoc. 2018;13:2330–47. https://doi.org/10.1038/s41596-018-0040-7.

Article  CAS  PubMed  Google Scholar 

Dandekar M, Tseng JR, Gambhir SS. Reproducibility of ¹⁸F-FDG microPET studies in mouse tumor xenografts. J Nucl Med. 2007;48:602–7. https://doi.org/10.2967/jnumed.106.036608.

Article  PubMed  Google Scholar 

Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA: A Cancer J Clin. 2017;67:507–24. https://doi.org/10.3322/caac.21411.

Article  Google Scholar 

Wu Q, Huang G, Wei W, Liu J. Molecular imaging of renal cell carcinoma in precision medicine. Mol Pharm. 2022;19:3457–70. https://doi.org/10.1021/acs.molpharmaceut.2c00034.

Article  CAS  PubMed  Google Scholar 

Pal SK, Forero-Torres A, Thompson JA, Morris JC, Chhabra S, Hoimes CJ, et al. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma. Cancer. 2019;125:1124–32. https://doi.org/10.1002/cncr.31912.

Article  CAS  PubMed  Google Scholar 

Yang M, Tang X, Zhang Z, Gu L, Wei H, Zhao S, et al. Tandem CAR-T cells targeting CD70 and B7–H3 exhibit potent preclinical activity against multiple solid tumors. Theranostics. 2020;10:7622–34. https://doi.org/10.7150/thno.43991.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, et al. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Investig New Drugs. 2014;32:1246–57. https://doi.org/10.1007/s10637-014-0151-0.

Article  CAS  Google Scholar 

Owonikoko TK, Hussain A, Stadler WM, Smith DC, Kluger H, Molina AM, et al. First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother Pharmacol. 2015;77:155–62. https://doi.org/10.1007/s00280-015-2909-2.

Article  CAS  PubMed  Google Scholar 

Massard C, Soria J-C, Krauss J, Gordon M, Lockhart AC, Rasmussen E, et al. First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma. Cancer Chemother Pharmacol. 2019;83:1057–63. https://doi.org/10.1007/s00280-019-03796-4.

Article  CAS